---

Thalassemia in Pediatrics

Definition and Genetics

1. Deficiency of functional hemoglobin (HbA) → hypochromic, microcytic red cells
2. Excess unpaired globin chains that precipitate within erythroid precursors → membrane damage, ineffective erythropoiesis, and hemolysis

• Beta-globin gene: chromosome 11 (single gene per haploid genome)
• Alpha-globin genes: chromosome 16 (two genes per haploid genome, four total)
• Autosomal codominant inheritance
• Endemic in Mediterranean, Middle East, tropical Africa, Indian subcontinent, and Southeast Asia - consistent with a heterozygote protective effect against falciparum malaria
• Robbins & Kumar Basic Pathology, p. 602
• Harrison's Principles of Internal Medicine 22E, p. 820

---

Classification

Beta-Thalassemia

• Splicing mutations - most common cause of beta+ thalassemia
• Promoter region mutations - reduce transcription by 75-80%; cause beta+ thalassemia
• Chain terminator / frameshift mutations - most common cause of beta0 thalassemia (no beta-globin produced)

Alpha-Thalassemia

---

Pathophysiology

• Excess alpha-chains precipitate in erythroid precursors
• Inclusions cause membrane lipid oxidation and damage
• Most precursors are destroyed in the bone marrow before reaching circulation
• This drives:
  • Massive bone marrow expansion ("chipmunk" facies, "hair on end" skull X-ray, pathologic fractures)
  • Hepatosplenomegaly (extramedullary hematopoiesis + hemolysis)
  • Increased intestinal iron absorption
  • Iron overload in liver, heart, and endocrine organs (even without transfusions, but vastly worsened by them)

• Severe growth retardation
• Frontal bossing, maxillary overgrowth
• Hepatosplenomegaly
• Pathologic bone fractures
• Progressive cardiopulmonary failure

---

Clinical Features in Children

Presentation

• Beta-thalassemia major typically presents at 6-24 months of age, when HbF production physiologically declines and the switch to beta-globin synthesis is expected
• Progressive pallor, failure to thrive, abdominal distension from hepatosplenomegaly
• Jaundice (hemolytic)
• Characteristic facies from bone marrow expansion if undertreated

Physical findings

• Pallor, jaundice, scleral icterus
• Massive splenomegaly (may also enlarge liver)
• Bony deformities: prominent malar eminences, frontal bossing, "hair on end" calvarium on skull X-ray
• Growth retardation

---

Diagnosis

Laboratory

• CBC: severe microcytic, hypochromic anemia; Hb 2-4 g/dL in thalassemia major
• Peripheral smear: target cells, hypochromic cells, nucleated red cells, basophilic stippling
• Elevated reticulocytes; elevated bilirubin (indirect)
• Elevated serum ferritin and iron
• HPLC (high-performance liquid chromatography): elevated HbF (90-100%), absent or minimal HbA, elevated or normal HbA2 in beta-thalassemia major

Genetic testing

• Mutation analysis of beta-globin gene is essential before genetic counseling and antenatal diagnosis
• Sequencing identifies the specific mutation(s) - critical for predicting phenotype severity

Heterozygotes (thalassemia minor/trait)

• Mild microcytic anemia or normal Hb
• Elevated HbA2 (>3.5%) on HPLC is the key diagnostic finding
• Must be distinguished from iron deficiency anemia (which lowers HbA2)

---

Management

1. Regular Blood Transfusions (Transfusion-Dependent Thalassemia)

• Goal: maintain pre-transfusion Hb >9-10.5 g/dL to suppress ineffective erythropoiesis, allow normal growth and development, and prevent bone changes
• Frequency: every 2-5 weeks
• Use leukoreduced packed red cells to minimize alloimmunization and transfusion reactions
• Well-transfused children have relatively normal growth and can enter puberty
• Decision to initiate lifelong transfusion: based on definitive diagnosis, severity of anemia on repeated measurement, degree of ineffective erythropoiesis, and clinical criteria (failure to thrive, bone changes)

2. Iron Chelation Therapy

• Initiate when serum ferritin >1000 ng/mL or after ~10-20 transfusions, typically by age 2-3 years
• Monitor iron burden with liver MRI (R2 or T2)** and cardiac MRI (T2)* - critical for guiding chelation intensity

• Cardiac iron (assessed by T2* MRI) is the key predictor of heart failure and arrhythmia - the leading cause of death in undertreated patients

3. Splenectomy

• Considered when annual blood consumption increases progressively causing significant increase in iron stores despite good chelation, or in the presence of symptomatic hypersplenism
• Post-splenectomy infection is a major risk (especially encapsulated organisms: Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)
• Vaccinate against all encapsulated organisms prior to splenectomy
• Prophylactic penicillin post-splenectomy (particularly in young children)
• Splenectomy may be delayed or avoided with optimal transfusion management

4. Hematopoietic Stem Cell Transplantation (HSCT)

• The traditional curative option
• Matched sibling donor HSCT is curative in >80% of cases
• Best results in youngest, well-chelated patients with fewer prior transfusions
• Only ~1/3 of patients have matched sibling donors
• Risks: graft failure, graft rejection, graft-versus-host disease (GVHD), transplant-related mortality 5-20%
• Haploidentical and unrelated donor results are improving

5. Gene Therapy (Approved, Cutting-Edge)

1. CRISPR/Cas9 editing (Casgevy - exa-cel): Downregulates BCL11A to reactivate HbF production. Results: Hb ≥12 g/dL and HbF ≥10 g/dL, leading to transfusion independence in >90% of patients aged 12-35
2. Lentiviral gene addition (betibeglogene autotemcel - beti-cel): Inserts a functional beta-globin gene (HbA^T87Q). Best results in non-beta0/beta0 genotypes, though higher viral titers have improved outcomes in beta0/beta0

6. Adjuncts

• Folic acid supplementation (chronic hemolysis depletes folate)
• Luspatercept (erythroid maturation agent): reduces transfusion requirements in adults; evidence is expanding
• Hydroxyurea: beneficial in some non-transfusion-dependent patients and HbE-beta thalassemia by raising HbF

---

Complications in Children

---

HbH Disease in Children

• HbH patients have Hb ~8-9 g/dL and generally do not need regular transfusions
• Folic acid 2-5 mg/day is recommended, especially in pediatric patients
• Hemolytic crises may occur during acute infections - require prompt blood transfusion and infection treatment
• Avoid oxidant drugs

---

Thalassemia Minor (Trait) in Children

• No specific treatment required
• Genetic counseling for parents is essential
• During pregnancy (for carrier mothers): monitor during 2nd and 3rd trimesters; folic acid support
• If true iron deficiency coexists: iron supplementation with monitoring of ferritin and transferrin saturation
• Do not administer empiric iron to children with thalassemia trait presenting with microcytic anemia (will worsen iron overload)

---

Key Points Summary

• Thalassemia major presents in infancy/early childhood; diagnosis confirmed by HPLC showing markedly elevated HbF
• Treatment foundation: regular transfusions (Hb target >9-10.5 g/dL) + iron chelation (typically starting age 2-3 years)
• Cardiac iron overload (T2* MRI) is the most feared complication - the leading cause of death
• HSCT from a matched sibling offers cure in >80%; best outcomes in youngest, well-chelated patients
• Gene therapy (CRISPR-based and lentiviral) is now approved and achieves transfusion independence in >90% of eligible patients
• Post-splenectomy: lifelong penicillin prophylaxis and vaccinations against encapsulated organisms

---

• Harrison's Principles of Internal Medicine, 22E (2025), Chapter 103
• Goldman-Cecil Medicine, International Edition
• Robbins & Kumar Basic Pathology
• Robbins, Cotran & Kumar Pathologic Basis of Disease

---

Severe Acute Malnutrition (SAM) in Pediatrics

Definition

---

Classification: The SAM Spectrum

• Somatic compartment: skeletal muscle proteins - depleted more in marasmus
• Visceral compartment: liver and organ proteins (albumin, transferrin) - depleted more in kwashiorkor

1. Marasmus ("Dry" SAM)

• Body catabolizes somatic (muscle) protein for energy
• Visceral compartment relatively preserved - serum albumin normal or near-normal
• Subcutaneous fat mobilized as fuel
• Low leptin stimulates hypothalamic-pituitary-adrenal axis → high cortisol → lipolysis

• Weight <60% of expected for age/height/sex
• Severe muscle wasting and loss of subcutaneous fat
• Emaciated extremities - "old man face" with head appearing disproportionately large for body
• No edema
• Dry, thin, pale, lax, and wrinkled skin
• Fine lanugo-like hair; thin, slow-growing hair that falls out
• Anemia (multivitamin deficiency)
• Immune deficiency (T-cell-mediated) → recurrent infections
• Growth retardation

2. Kwashiorkor ("Wet" or Edematous SAM)

• Visceral protein compartment severely depleted → hypoalbuminemia
• Hypoalbuminemia → reduced plasma oncotic pressure → generalized/dependent edema
• Reduced synthesis of lipoprotein carrier proteins → fat cannot be exported from liver → fatty liver
• True weight loss masked by fluid retention; weight typically 60-80% of expected

• Bilateral pitting edema (puffiness of face, hands, and legs; ascites)
• Relatively preserved subcutaneous fat and muscle (masked by edema)
• Hepatomegaly (fatty liver)
• Characteristic skin lesions: alternating zones of hyperpigmentation, desquamation, and hypopigmentation ("flaky paint" dermatosis)
• Hair changes: loss of color, alternating bands of pale and darker color ("flag sign" / signe de la bandera), straightening, fine brittle texture, easy hair pull
• Apathy, listlessness, irritability, loss of appetite
• Small bowel mucosal atrophy → disaccharidase deficiency → may not tolerate full-strength milk-based feeds initially
• Immune deficiency → secondary infections
• Anemia (multifactorial: iron, folate, protein deficiency + chronic infection)

3. Marasmic Kwashiorkor

---

---

---

Marasmus vs. Kwashiorkor - Comparison

---

Pathology (Morphology)

• Growth failure (universal)
• Peripheral edema in kwashiorkor
• Loss of body fat and muscle atrophy (more marked in marasmus)
• Liver: enlarged and fatty in kwashiorkor (not marasmus); superimposed cirrhosis is rare
• Small bowel: decreased mitotic cells, mucosal atrophy, loss of villi and microvilli in kwashiorkor → disaccharidase deficiency (especially lactase)
• Bone marrow: hypoplastic with decreased red cell precursors
• Thymus and lymphoid tissue: atrophy (more in kwashiorkor)
• Brain (in infants with early-onset SAM): cerebral atrophy, reduced neurons, impaired myelination

---

Early Detection and Screening

• Growth charts (weight monitoring) - the most practical field tool
• Skinfold thickness (subcutaneous fat)
• Mid-arm circumference (somatic protein reserve)
• Serum albumin and transferrin (visceral protein reserve)

---

Management: WHO 10-Step Protocol

Triage: Who Needs Inpatient Admission?

• Severe edema (grade 3) or edema with complications
• Severe anorexia (fails appetite test)
• Altered consciousness / convulsions
• Severe dehydration
• Respiratory distress / pneumonia
• Fever >39°C or hypothermia <35.5°C
• Severe anemia or signs of shock
• Hypoglycemia

Phase 1 - Stabilization (Days 1-7): Treat Life-Threatening Conditions

• Blood glucose <3 mmol/L (<54 mg/dL) = emergency
• Give 50 mL of 10% dextrose or 10% sucrose orally/NGT, OR 5 mL/kg 10% dextrose IV
• Start feeds immediately every 2-3 hours (F-75)
• Never fast a SAM child

• Temperature <35.5°C rectally or <36°C axillary
• Warm the child (skin-to-skin, blankets, warm room); avoid draughts
• Feed every 2 hours (generates heat)

• SAM children are often dehydrated but IV fluids are dangerous (risk of cardiac overload)
• Use ReSoMal (Rehydration Solution for Malnutrition) - lower sodium, higher potassium and glucose than standard ORS
• 5 mL/kg every 30 minutes for 2 hours (oral/NGT), then 5-10 mL/kg/hr alternating with F-75 for up to 10 hours
• IV fluid ONLY for severe shock or cholera; use Ringer's lactate + 5% dextrose at 15 mL/kg/hr

• SAM children have excess body sodium but deficient intracellular potassium and magnesium
• Use electrolyte/mineral solution (potassium + magnesium + zinc) added to feeds
• Do NOT give diuretics for edema (dangerous - electrolyte depletion)
• Do NOT give iron during stabilization phase (potentiates infections, generates free radicals)

• Even without obvious signs of infection, assume infection exists in SAM
• Routine antibiotic therapy: amoxicillin (or ampicillin + gentamicin if severely ill) for all SAM children
• Treat specific infections as identified
• Immunize against measles (if not done) once condition stable (but not in shock)

• Give daily for at least 2 weeks:
  • Folic acid (5 mg on day 1, then 1 mg/day)
  • Zinc (2 mg/kg/day)
  • Copper (0.3 mg/kg/day)
  • Multivitamins
  • Vitamin A (only if signs of deficiency or recent measles): 200,000 IU on days 1, 2, and 14
• Do NOT give iron in Phase 1 - wait until Phase 2 (rehabilitation)

• F-75 therapeutic milk: 75 kcal/100 mL, 0.9 g protein/100 mL (low protein, low sodium, low osmolarity)
• Initial volume: 100 mL/kg/day divided every 2-3 hours (8-12 feeds/day)
• Purpose: repair metabolic processes without overwhelming the gut or heart; not for weight gain yet
• If child cannot eat: give by nasogastric tube

Phase 2 - Rehabilitation (Weeks 2-6+): Intensive Feeding and Catch-up Growth

• Transition to F-100 (100 kcal/100 mL, 2.9 g protein/100 mL) or RUTF (Ready-to-Use Therapeutic Food)
• RUTF (e.g., Plumpy'Nut): peanut-paste-based, 500 kcal/92g sachet, lipid-based, does not require refrigeration, can be given at home
• Volume increases stepwise to 150-220 mL/kg/day
• Target weight gain: >10 g/kg/day indicates successful catch-up
• Now add iron: 3 mg/kg/day elemental iron
• Stimulation: emotional and physical (structured play, sensory stimulation)
• Continue antibiotics if infection ongoing

• Cheerful, stimulating environment
• Structured play therapy 15-30 min/day
• Tender loving care; involve mother/caregiver

---

Discharge Criteria

• MUAC ≥12.5 cm (or WHZ ≥-2 SD)
• No edema for at least 2 weeks
• Eating well, alert and active
• No acute medical issues
• Caregiver education complete

---

Complications of SAM

---

Community-Based Management (CMAM)

• RUTF given weekly at health facility
• Regular MUAC/weight monitoring
• Caregiver education on feeding and hygiene
• Treatment of simple infections (amoxicillin 7-day course)
• Has dramatically expanded SAM treatment coverage in resource-limited settings

---

Prevention (WHO/FAO Framework)

1. Exclusive breastfeeding for 6 months, continued to 2 years
2. Appropriate complementary feeding (introducing protein and energy-rich foods at 6 months)
3. Immunization (especially measles, which precipitates kwashiorkor)
4. Growth monitoring with regular weight charting
5. Vitamin A supplementation (6-monthly in deficient populations)
6. Zinc supplementation to reduce diarrhea severity/duration
7. Safe water, sanitation, and hygiene
8. Treatment of intestinal parasites
9. Family planning and birth spacing

---

Key Points Summary

• SAM diagnosis: WHZ <-3 SD, MUAC <115 mm (field cut-off), or bilateral pitting edema
• Marasmus = calorie + protein deficiency; somatic wasting; no edema; albumin near-normal
• Kwashiorkor = predominantly protein deficiency; edema; fatty liver; hypoalbuminemia; skin and hair changes
• Management: WHO 10-step protocol in two phases (stabilization with F-75, then rehabilitation with F-100/RUTF)
• Critical early dangers: hypoglycemia, hypothermia, sepsis, refeeding syndrome, cardiac overload from IV fluids
• Do NOT give iron in Phase 1; do NOT give standard ORS (use ReSoMal); do NOT give IV fluids unless in shock
• Community-based RUTF programs have transformed SAM care globally

---

• Robbins & Kumar Basic Pathology, Chapter 7
• Robbins, Cotran & Kumar Pathologic Basis of Disease, Chapter 9
• Park's Textbook of Preventive and Social Medicine, Chapter on nutrition

---

Bronchopneumonia in Pediatrics

Definition

• Lobar pneumonia: homogeneous consolidation of an entire lobe or large portion
• Bronchopneumonia: patchy, segmental, bilateral, often basal consolidation

---

Anatomy of Distribution

---

Epidemiology and Importance

• One of the leading causes of death in children under 5 years globally
• Pneumonia accounts for approximately 14% of all deaths in children under 5
• Most deaths occur in low- and middle-income countries
• RSV is the most common cause in infants; S. pneumoniae predominates in older children

---

Etiology by Age Group

• S. aureus: produces severe necrotizing bronchopneumonia; common post-influenza; associated with lung abscess and pneumatoceles
• H. influenzae (non-encapsulated): produces bronchopneumonic pattern
• Viral: RSV, metapneumovirus, parainfluenza, influenza, adenovirus - especially in children <2 years; damage to respiratory epithelium predisposes to secondary bacterial infection
• Viral and bacterial co-infection is common and worsens prognosis

---

Pathogenesis

1. Organisms reach the lower respiratory tract via inhalation (most common), aspiration of upper airway secretions, or hematogenous spread
2. Infection begins in the bronchi and bronchioles (unlike lobar pneumonia which starts in alveoli)
3. Epithelial ulceration of bronchiolar walls occurs
4. Fibrinopurulent exudate (neutrophil-rich) fills the lumen and spreads into surrounding peribronchiolar alveolar spaces
5. Impaired mucociliary clearance promotes spread; gravity pulls secretions to lower lobes (bilateral basal distribution)
6. Viral infection particularly damages the respiratory epithelium → impairs mucociliary clearance → predisposes to secondary bacterial pneumonia

• Young age (immature immunity, smaller airways)
• Malnutrition (especially SAM - increases case fatality 9-fold)
• Lack of breastfeeding
• Indoor air pollution and smoke exposure
• Crowded living conditions
• Incomplete vaccination (measles, H. influenzae type b, S. pneumoniae vaccines)
• Prematurity and low birth weight
• Underlying conditions: congenital heart disease, CF, immune deficiency, sickle cell disease

---

Pathology (Morphology)

• Focal areas of consolidation, slightly elevated, dry, granular, gray-red to yellow
• Often bilateral and basal (dependent areas due to secretion pooling)
• Multilobar involvement common
• Poorly demarcated margins (contrast with sharp lobar boundary in lobar pneumonia)

• Neutrophil-rich exudate filling bronchi, bronchioles, and adjacent alveolar spaces
• Epithelial ulceration of bronchiolar walls
• Areas of consolidation: air replaced by suppurative exudate
• Unlike lobar pneumonia, no uniform staging (no red hepatization → gray hepatization)

---

Clinical Features

Symptoms

• Fever (high grade, often abrupt onset)
• Cough (may be productive in older children; often dry or tight in infants)
• Rapid breathing / tachypnea - the most sensitive and specific sign
• Difficulty breathing, respiratory distress
• Chest pain (pleuritic if pleuritis develops)
• Poor feeding, lethargy (especially in infants)
• Preceding upper respiratory tract infection (URTI) in many cases

Signs

• Tachypnea (see WHO respiratory rate thresholds below)
• Subcostal/intercostal recession (indrawing)
• Nasal flaring, grunting (especially in young infants)
• Reduced air entry on auscultation
• Crackles (crepitations) - fine inspiratory crackles at affected areas
• Bronchial breathing over consolidated segments
• Dullness to percussion over consolidated areas
• Fever, signs of toxicity
• Cyanosis (in severe disease)
• In infants: abdominal distension (swallowed air), poor feeding

---

WHO/IMCI Classification of Pneumonia in Children

Respiratory Rate Thresholds for Tachypnea (WHO):

Classification:

General Danger Signs (any age):

• Cannot drink or breastfeed
• Vomits everything
• Convulsions
• Lethargic or unconscious
• Grunting (in young infants)
• Central cyanosis

---

Investigations

Chest X-Ray

• Bronchopneumonia: patchy, bilateral, multifocal opacities predominantly in lower zones; ill-defined margins; perihilar infiltrates
• Lobar consolidation: homogeneous opacity of an entire lobe
• Peribronchial thickening (especially with viral etiology)
• Hyperinflation suggests viral or bronchiolitic component
• Complications: pleural effusion, empyema, pneumatocele (especially S. aureus), abscess, pneumothorax

Note: CXR alone cannot reliably distinguish viral from bacterial pneumonia

Blood Tests

• CBC: leukocytosis with neutrophilia (bacterial); lymphocytosis (viral); leukopenia in severe sepsis
• CRP, procalcitonin: elevated in bacterial (procalcitonin >0.25-0.5 ng/mL favors bacterial)
• Blood culture: positive in only ~10-30% of bacterial pneumonia; should be obtained before antibiotics in hospitalized children

Microbiology

• Nasopharyngeal swab + multiplex PCR (most sensitive for viral etiology: RSV, influenza, metapneumovirus)
• Sputum (difficult to obtain in children <6 years)
• Urine pneumococcal antigen (useful in older children/adults)
• Pleural fluid culture and microscopy if effusion present

Pulse Oximetry

• Essential in all children with respiratory illness
• SpO2 <90% = significant hypoxemia; indicates need for oxygen therapy

---

Management

Outpatient Management (Non-severe Pneumonia)

• Give folic acid, ensure adequate hydration, nutrition
• Educate caregiver on danger signs: if no improvement in 48 hours OR develops danger signs → return immediately
• Reassess in 2 days

Inpatient Management (Severe/Very Severe Pneumonia)

• Indicated when SpO2 <90% (or <92% in children with underlying cardiac/lung disease)
• Deliver via nasal prongs, face mask, or headbox (infants)
• Target SpO2 ≥94%
• High-flow nasal cannula (HFNC) for moderate-severe hypoxemia

• Antipyretics (paracetamol/acetaminophen for fever and comfort; avoid ibuprofen if dehydrated)
• IV fluids if cannot take orally (avoid overhydration - risk of SIADH in pneumonia)
• NG tube feeding if poor oral intake
• Chest physiotherapy: not routinely recommended in acute phase
• Bronchodilators: only if wheeze present (suggests bronchiolitic component or reactive airway disease)
• Mucolytics/antihistamines: not recommended

• Respiratory rate, heart rate, SpO2, temperature - at least every 4 hours
• Fluid balance
• Response to antibiotics expected within 48-72 hours

---

Complications

---

Bronchopneumonia vs Lobar Pneumonia: Comparison

---

Specific Pneumonia Patterns in Children

Staphylococcal Pneumonia

• Severe, rapidly progressive bronchopneumonia
• Characteristic pneumatoceles (thin-walled air cysts) on CXR
• May develop empyema, pneumothorax, lung abscess
• Often follows influenza infection
• Requires anti-staphylococcal coverage (Cloxacillin IV; Vancomycin if MRSA)

Mycoplasma Pneumonia ("Walking Pneumonia")

• Most common atypical pathogen in school-age children
• Gradual onset; child often not very ill despite CXR changes
• Dry, hacking cough; myalgias; headache; low-grade fever
• CXR: diffuse bilateral patchy infiltrates, often worse than expected clinically
• Treatment: Azithromycin or Clarithromycin (macrolides); or Doxycycline in >8 years

Chlamydia trachomatis Pneumonia (Infants 1-3 months)

• Afebrile pneumonitis - characteristic feature
• Staccato cough, tachypnea, bilateral diffuse infiltrates
• Often with concurrent conjunctivitis
• Treatment: Erythromycin or Azithromycin (macrolide)

RSV Bronchiolitis-Pneumonia Overlap

• In infants <2 years; RSV is the dominant pathogen
• Wheeze, hyperinflation, bilateral peribronchial thickening
• Usually managed supportively (no proven benefit of antivirals in immunocompetent children)

---

Prevention

1. Vaccines - most effective intervention:
   • Pneumococcal conjugate vaccine (PCV13/PCV15): major impact on S. pneumoniae pneumonia
   • H. influenzae type b (Hib) vaccine: prevents Hib pneumonia/meningitis
   • Measles vaccine: measles is a major predisposing cause of pneumonia in developing countries
   • Influenza vaccine: annual, recommended from 6 months
   • RSV prophylaxis: Nirsevimab (monoclonal antibody) for infants <12 months in first RSV season
2. Breastfeeding: exclusive breastfeeding for 6 months reduces pneumonia risk significantly
3. Nutrition: prevent malnutrition (especially vitamin A and zinc deficiencies)
4. Vitamin A supplementation: reduces pneumonia case fatality
5. Zinc supplementation: reduces incidence and duration of pneumonia
6. Reduce indoor air pollution: avoid cooking smoke, tobacco smoke exposure
7. Hand hygiene and sanitation
8. Zinc: reduces pneumonia incidence by ~41% in deficient populations

---

Key Points Summary

• Bronchopneumonia = patchy lobular consolidation starting in bronchioles; most common pneumonia pattern in infants and young children
• Etiology is age-dependent: viruses (RSV) dominate in infants; S. pneumoniae and Mycoplasma in older children
• Tachypnea is the most important clinical sign - use WHO age-specific thresholds
• WHO IMCI classifies severity based on respiratory rate + chest indrawing + danger signs
• Outpatient non-severe: oral amoxicillin; inpatient severe: IV ampicillin ± gentamicin
• S. aureus pneumonia: suspect if pneumatoceles, cavitation, or rapid deterioration → add anti-staphylococcal agent
• Atypical (Mycoplasma): school-age children, gradual onset, macrolide therapy
• Complications: empyema, abscess, pneumatocele, bacteremia, SIADH
• Prevention: PCV, Hib, measles vaccines + breastfeeding + nutrition are the pillars

---

• Robbins & Kumar Basic Pathology, Chapter 11 (p. 469-471)
• Fishman's Pulmonary Diseases and Disorders, 2-Volume Set, Chapter 122
• Robbins, Cotran & Kumar Pathologic Basis of Disease
• Goldman-Cecil Medicine, International Edition
• Harriet Lane Handbook, 23rd Edition (Johns Hopkins)

---

Nephrotic Syndrome in Pediatrics

Definition

• In children, the most common presentation is steroid-sensitive nephrotic syndrome (SSNS), with minimal change disease (MCD) as the underlying lesion
• Hypertension is not typical of minimal change NS; its presence suggests a different underlying etiology

---

Epidemiology

• Incidence: ~2-7 per 100,000 children per year
• Peak age: 2-6 years (preschool; median 2.5 years)
• Male:female ratio in young children: ~2:1 (equalizes in adolescence)
• Minimal change disease (MCD) accounts for:
  • ~90% of cases in children <10 years
  • ~70-80% of all pediatric NS overall
• FSGS is more prevalent in African-Americans, Hispanics, and Asians with NS

---

Classification

By Etiology

• Usually genetic (mutations in NPHS1 [nephrin], NPHS2 [podocin], WT1, LAMB2)
• Finnish type: most common; massive proteinuria from birth; placental enlargement
• Immunosuppression is not effective - managed conservatively then transplantation
• Infective causes: congenital syphilis, CMV, rubella, toxoplasmosis, HIV

• MCD, FSGS, mesangial proliferation, membranous nephropathy
• No identifiable systemic cause

• Accounts for ~10% in children
• Causes: lupus nephritis (SLE), IgA nephropathy, Henoch-Schönlein purpura (IgA vasculitis), hepatitis B/C, malaria, HIV, amyloidosis, malignancy (Hodgkin lymphoma → MCD)

By Histological Lesion (Primary NS)

By Steroid Response (Clinical Classification)

---

Pathophysiology

Why Proteinuria Occurs

• Normal glomerular filtration barrier consists of: fenestrated endothelium + glomerular basement membrane (GBM) + podocyte foot processes (filtration slits bridged by nephrin)
• In NS, loss of podocyte foot process architecture ("foot process effacement") disrupts the filtration barrier → massive protein leakage
• In MCD: T-cell-derived circulating permeability factor → podocyte injury → foot process effacement (visible only on electron microscopy - hence "minimal change" on light microscopy)
• In FSGS: progressive podocyte loss → segmental scarring of glomeruli

Pathophysiological Cascade

Podocyte injury
      ↓
Massive proteinuria (especially albumin)
      ↓
Hypoalbuminemia
      ↓
↓ Plasma oncotic pressure
      ↓
Fluid shifts to interstitium (underfill edema) + Primary renal Na⁺ retention (overfill)
      ↓
Generalized edema (periorbital, scrotal, ascites, pleural effusion)
      ↓
↑ Hepatic lipoprotein synthesis (response to ↓ oncotic pressure) + ↓ lipid clearance
      ↓
Hyperlipidemia (↑ cholesterol, LDL, VLDL) + Lipiduria (fatty casts)

• Underfill (especially MCD): low plasma volume → stimulated RAAS → secondary Na⁺ retention
• Overfill (other causes): primary renal Na⁺ retention → expanded plasma volume → suppressed RAAS

Consequences of Urinary Protein Loss

---

Clinical Features

Presentation

• Periorbital puffiness - often the earliest sign, noticed on waking; may be mistaken for allergy
• Dependent edema - legs, feet, sacral area
• Scrotal/labial edema (can be massive)
• Abdominal distension (ascites)
• Pleural effusion → dyspnea in severe cases
• Weight gain (fluid)
• Decreased urine output (concentrated, frothy urine)
• Child appears generally well initially (in MCD)
• No hypertension, no gross hematuria in typical MCD

On Examination

• Pitting edema (periorbital, peripheral, sacral)
• Abdominal fullness/fluid thrill (ascites)
• Normal blood pressure (in MCD)
• No rash (in idiopathic primary NS)
• Signs of underlying cause if secondary (butterfly rash in SLE, purpura in HSP)

Urine Appearance

• Frothy urine (protein)
• Lipid droplets ("oval fat bodies"), fatty casts ("Maltese crosses" under polarized light)
• Microscopic hematuria in ~20% (macroscopic hematuria is unusual - suggests different diagnosis)

---

Investigations

Urine

• Urine dipstick: 3+ or 4+ protein (screening; Albustix)
• Spot urine protein:creatinine ratio (PCR): >2.0 mg/mg (or >200 mg/mmol) = nephrotic range
• 24-hour urine protein: >40 mg/m²/hr in children
• Microscopy: fatty casts, oval fat bodies, lipid droplets
• Urine sodium: low (<20 mmol/L) in underfill state

Blood

• Serum albumin: <2.5 g/dL (often <1.5 g/dL in severe cases)
• Serum cholesterol: elevated (>200 mg/dL); LDL, VLDL elevated
• Serum electrolytes (may show hyponatremia from dilution)
• Serum creatinine and urea (usually normal in MCD; elevated in SRNS)
• Complement C3, C4: normal in MCD and primary NS; low C3 suggests postinfectious GN, MPGN; low C3+C4 suggests lupus
• ANA, anti-dsDNA, ANCA (to exclude SLE, vasculitis)
• Hepatitis B, C serology; HIV
• CBC: may show elevated hematocrit (hemoconcentration)
• Coagulation screen (hypercoagulable state)

Renal Biopsy

• Age 1-12 years
• No hypertension
• No macroscopic hematuria
• Normal complement
• No systemic features (rash, arthritis)

• Age <1 year (exclude congenital NS) or adolescent (higher chance of FSGS/MN)
• Macroscopic hematuria
• Persistent hypertension
• Low complement levels
• Extrarenal features (rash, arthritis)
• Steroid resistance (after 6-8 weeks of treatment)
• Atypical features

---

Management

Initial Treatment (First Presentation)

• 60 mg/m²/day (max 60 mg/day) or 2 mg/kg/day (max 60 mg/day) as daily dose for 4-6 weeks
• Then switch to alternate-day dosing: 40 mg/m² alternate days for 2-3 months, with gradual taper over 5-6 months total
• Total initial course: at least 12 weeks (longer courses reduce relapse rates - KDIGO 2025 recommends 3-6 months)

• Complete remission: urine dipstick trace/negative for 3 consecutive days (or urine PCR <0.2 mg/mg)
• ~90% of children with MCD achieve remission within 2-4 weeks of treatment

Steroid-Sparing Agents (for FRNS/SDNS)

Steroid-Resistant NS (SRNS)

• Defined: no remission after 6-8 weeks of full-dose daily prednisone
• Biopsy required (most will have FSGS)
• Check for genetic mutations (NPHS1, NPHS2, WT1, TRPC6, etc.) - ~30 genes identified
• Genetic SRNS: typically does not respond to any immunosuppression
• Treatment options:
  • Calcineurin inhibitors (Tacrolimus or Cyclosporine) - first-line for non-genetic SRNS
  • Add low-dose prednisone
  • MMF as alternative or combination
  • IV pulse methylprednisolone
  • Rituximab in resistant cases
  • ACE inhibitor / ARB - antiproteinuric effect regardless of response to immunosuppression
• Prognosis: up to 50% of SRNS children (especially FSGS) progress to end-stage kidney disease (ESKD) within 10 years

Congenital NS (<3 months)

• Immunosuppression is NOT effective - do not give steroids
• Conservative management:
  • Sodium and fluid restriction
  • Intermittent IV albumin + loop diuretics (furosemide) for severe edema
  • Hypercaloric diet (nasogastric if needed)
  • Thyroid hormone replacement (T4 lost in urine)
  • ACE inhibitor/ARB to reduce proteinuria
  • Prophylactic anticoagulation if severe (renal vein thrombosis risk)
  • Bilateral nephrectomy → dialysis → renal transplantation (definitive treatment)

Membranous Nephropathy in Children

• Usually secondary (hepatitis B, SLE, PLA2R antibodies)
• ACE inhibitor/ARB + low-salt diet first
• Steroids + alkylating agents OR CNIs for progressive cases
• MMF and rituximab promising especially in PLA2R-antibody positive

---

Supportive Management

Edema

• Dietary sodium restriction (low-salt diet; <2 g Na/day)
• Fluid restriction only if severe hyponatremia
• Furosemide (loop diuretic): 1-2 mg/kg/dose PO/IV; for symptomatic edema
• Spironolactone (aldosterone antagonist): useful as adjunct (aldosterone elevated in underfill)
• IV 20% albumin infusion followed by furosemide: for severe symptomatic edema or refractory edema; not routinely recommended as it is transiently lost in urine
• A fractional sodium excretion <0.2% differentiates volume-contracted (caution with diuretics) from volume-expanded states

Infection Prevention and Management

• Children with NS are immunocompromised (urinary loss of immunoglobulins + steroids)
• Spontaneous bacterial peritonitis (SBP): 2-6% incidence; most commonly S. pneumoniae and gram-negatives
  • Suspect in any febrile child with NS and abdominal pain
  • Diagnosis: paracentesis (PMN >250/mm³)
  • Treatment: IV cefotaxime or ceftriaxone
• Pneumococcal vaccine: give before starting steroids if possible; revaccinate every 5 years
• Varicella (chickenpox): can be severe/fatal in children on high-dose steroids
  • Varicella-exposed non-immune children on steroids → IV acyclovir or VZIg
  • Stop steroids if varicella develops (if possible) and give IV acyclovir
• Avoid live vaccines while on high-dose steroids (>2 mg/kg/day for >2 weeks)
• Prophylactic penicillin V during active nephrotic syndrome (some centers)

Thromboembolism

• All nephrotic patients are hypercoagulable (loss of antithrombin III, protein C, protein S)
• Up to 20% experience thrombotic events (deep vein thrombosis, pulmonary embolism, renal vein thrombosis)
• Renal vein thrombosis: suspect with loin pain, hematuria, sudden worsening of renal function; especially with proteinuria >10 g/day and albumin <2 g/dL (membranous nephropathy carries highest risk)
• Prophylactic anticoagulation: considered in high-risk patients (albumin <2 g/dL, immobile, membranous nephropathy)
• Therapeutic anticoagulation (LMWH or warfarin) for established thrombosis

Hyperlipidemia

• Statin therapy if persistent nephrotic syndrome with prolonged hyperlipidemia
• Usually resolves with remission

Diet

• Low salt (sodium restriction essential)
• Normal protein intake (protein restriction is no longer recommended - it worsens hypoalbuminemia without benefit)
• Adequate calories to maintain growth

Steroid Side Effects to Monitor (Long-term)

• Growth retardation (alternate-day dosing minimizes this)
• Obesity, cushingoid features
• Hypertension (monitor regularly)
• Cataracts and glaucoma (ophthalmology review)
• Osteoporosis: calcium + vitamin D supplementation recommended
• Glycosuria/diabetes
• Behavioral changes
• Increased infection susceptibility

---

Complications Summary

---

Prognosis

---

Key Points Summary

• Classic pediatric NS: 2-6 year old boy with periorbital puffiness and edema, frothy urine, normal BP, normal complement
• MCD accounts for ~90% of NS in children 1-10 years; diagnosis/treatment without biopsy is standard in typical presentation
• Steroid (prednisolone) 60 mg/m²/day × 4-6 weeks then alternate-day taper = first-line treatment
• ~90% of MCD responds; ~50% will have at least one relapse
• Biopsy is needed before treating SRNS (most will have FSGS)
• SRNS → genetic testing (30 known genes) + calcineurin inhibitors
• Hypercoagulability and infections (SBP, pneumococcal sepsis) are the most dangerous complications
• KDIGO 2025 guideline now emphasizes: longer initial steroid courses (3-6 months), updated algorithm for biopsy timing, and rituximab as effective steroid-sparing agent

---

• KDIGO 2025 Clinical Practice Guideline (Floege et al., Kidney Int 2025, PMID 40254362) - now includes updated treatment algorithms for steroid-sensitive, frequently-relapsing, steroid-dependent, and steroid-resistant NS, incorporating rituximab as a primary steroid-sparing agent
• Cochrane Review on corticosteroid therapy for NS in children (Hahn et al., Cochrane Database Syst Rev 2024, PMID 39171624) - confirms prolonged initial therapy reduces relapse rates
• Cochrane Review on steroid-resistant NS in children (Liu et al., Cochrane Database Syst Rev 2025, PMID 40337980) - updated evidence for CNIs, MMF, rituximab

• Campbell-Walsh Urology, 3-Volume Set (Chapter on Nephrotic Syndrome in children)
• Brenner and Rector's The Kidney, 2-Volume Set
• National Kidney Foundation Primer on Kidney Diseases, 8e
• KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children

---

The Normal Newborn in Pediatrics

Definition: Periods and Terms

• Neonatal period: first 28 days of life (0-28 days)
• Newborn/neonate: birth to 28 days
• Term infant: 37-42 completed weeks of gestation
• Preterm: <37 weeks; Post-term: >42 weeks
• Normal birth weight: 2,500-4,000 g

---

1. Anthropometry at Birth (Normal Term Infant)

Weight Classification by Gestational Age

• AGA (Appropriate for gestational age): weight between 10th and 90th percentile
• SGA (Small for gestational age): weight <10th percentile - at risk for hypoglycemia, temperature instability
• LGA (Large for gestational age): weight >90th percentile - often born to mothers with uncontrolled diabetes; at risk for hypoglycemia, shoulder dystocia, birth trauma

---

2. Vital Signs (Normal Term Newborn)

• Tachypnea = respiratory rate >60 breaths/min
• Normal newborns may have periodic breathing (irregular respiratory rhythm with brief pauses up to 10 seconds) - normal; distinguish from true apnea (>20 sec pause)

---

3. Apgar Score

• 7-10: Normal
• 4-6: Moderate depression; stimulation and/or supplemental oxygen
• 0-3: Severe depression; immediate resuscitation required

A low Apgar score at 1 minute is not predictive of long-term neurologic outcome. A score of 0-3 at 5 minutes correlates with increased risk of neonatal death. Resuscitation must NOT be interrupted to calculate the Apgar score.

---

4. Gestational Age Assessment: Ballard Score

Neuromuscular Maturity Criteria:

Physical Maturity Criteria:

---

5. Physical Examination of the Normal Newborn

General

• Well-flexed posture; symmetric movements
• Vigorous cry; responsive to stimuli
• Skin may show acrocyanosis (blue hands and feet) in first few hours - normal; central cyanosis is abnormal
• Vernix caseosa: white, greasy material covering the skin at birth (more in preterm)

---

Head

• Molding: overlapping of skull bones from passage through birth canal; resolves in 48-72 hours
• Caput succedaneum: diffuse, edematous swelling of the scalp; crosses suture lines; present at birth; resolves in 1-3 days
• Cephalhematoma: subperiosteal hemorrhage; does NOT cross suture lines; appears after birth; may take weeks to resolve; associated with jaundice
• Anterior fontanelle: diamond-shaped; normally soft and flat; 1-4 cm; closes at 12-18 months
• Posterior fontanelle: triangular; closes by 6-8 weeks
• Skull sutures: sagittal, coronal, lambdoid, metopic - should be palpable; note any premature fusion (craniosynostosis)

---

Eyes

• Intermittent crossing of the eyes is normal in first few months (immature ocular control)
• Red reflex must be present bilaterally - absence suggests cataract, retinoblastoma, retinal detachment → urgent ophthalmology referral
• Subconjunctival hemorrhages: from birth trauma; resolve spontaneously
• Pupils equal and reactive to light
• Doll's eye reflex (oculocephalic reflex): head turns → eyes move opposite direction; present in newborns

---

Ears, Nose, Throat

• Ears: check position (low-set ears suggest chromosomal abnormality); pinna recoils instantly in term infant
• Check patency of nares (choanal atresia: obstruction → respiratory distress; test by passing small catheter)
• Epstein pearls: small white retention cysts on hard palate - normal; resolve in weeks
• Bohn nodules: similar cysts on gum margins - normal
• Palate must be palpated to exclude submucous cleft (not visible to inspection alone)
• Check for ankyloglossia (tongue tie): short frenulum; may affect breastfeeding

---

Chest and Lungs

• Gynecomastia in both male and female infants (maternal estrogen): normal; may express "witch's milk" (white milky discharge) - normal; resolves within weeks
• Clavicles: palpate for fracture (crepitus, asymmetric Moro, tenderness) - especially after shoulder dystocia
• Normal breath sounds bilateral and equal
• Tachypnea (RR >60) requires evaluation; grunting, nasal flaring, retractions indicate respiratory distress

---

Cardiovascular

• Heart rate 120-160 bpm
• Femoral pulses: must be palpated bilaterally; absent/weak femoral pulses suggest coarctation of the aorta
• Systolic murmur may be present in first 24-48 hours due to closing ductus arteriosus - usually benign; persistent murmur needs evaluation
• Patent ductus arteriosus (PDA): continuous "machinery" murmur; more common in preterm
• Four-limb blood pressure and pulse oximetry (right hand + foot) to screen for critical congenital heart disease

---

Abdomen

• Appears slightly full/rounded; soft
• Liver normally palpable 1-2 cm below costal margin (normal)
• Spleen tip may be barely palpable
• Kidneys may be palpable by deep palpation in first day
• Umbilical cord: 3 vessels (2 arteries + 1 vein); single umbilical artery (2-vessel cord) is associated with chromosomal abnormalities and renal/cardiac anomalies - evaluate further
• Cord separates in 7-14 days; keep dry; no routine alcohol recommended (delays separation)

---

Genitalia

• Testes: both fully descended into scrotum in term male
• Check for undescended testis (cryptorchidism): if unilateral and not descended by 6 months, refer for orchidopexy
• Hypospadias: urethral opening on ventral surface of penis (glanular most common); if present, do NOT circumcise (foreskin may be used in repair)
• Assess for hydrocele: transilluminates; usually resolves by 1 year
• Phimosis: physiological and normal in newborn (non-retractile foreskin)

• Labia majora covers minora in term females
• Vaginal discharge (white mucoid) and/or blood-tinged discharge: normal in first 2 weeks; due to maternal estrogen withdrawal ("pseudo-menstruation")
• Labial adhesions: thin film of tissue between labia minora; benign, resolves spontaneously
• Clitoromegaly suggests congenital adrenal hyperplasia (CAH) in an XX infant

---

Spine and Back

• Inspect full spine for neural tube defects: hairy patches, sacral dimples, soft tissue masses, hemangioma, skin discoloration
• Sacral dimples: common; those with intact base within 2.5 cm of anus are benign; deep, large, or non-visible-base dimples require spinal ultrasound

---

Hips - DDH Screening

• Risk factors: female sex, breech presentation, family history, oligohydramnios, first-born
• All newborns screened by:

• Ortolani maneuver: hip ABduction + pressure on greater trochanter → "clunk" as dislocated femoral head relocates = positive (reduces a dislocated hip)
• Barlow maneuver: hip ADduction + posterior pressure → "clunk" as femoral head dislocates = positive (dislocates an unstable hip)

• Positive exam → refer orthopedics
• Equivocal → re-examine at 2-week visit
• Breech (normal exam) or female with family history → hip ultrasound at 6 weeks

---

Skin - Normal Findings and Transient Conditions

---

6. Neurological Examination

Tone

• Term infant: strong flexion of all four extremities at rest
• Hypotonia ("floppy infant"): lies in frog-legged position; suggests Down syndrome, hypothyroidism, birth asphyxia, spinal muscular atrophy
• Hypertonia: spasticity or rigid movements; suggests HIE, drug withdrawal, meningitis

Primitive (Neonatal) Reflexes

• Asymmetric or absent primitive reflexes suggest neurological injury (birth trauma, nerve palsy, CNS lesion)
• Asymmetric Moro: suspect brachial plexus injury (Erb's palsy - C5-C6) or fractured clavicle
• Reflexes disappear as cortical control matures; persistence beyond expected age suggests CNS pathology

---

7. Physiological Adaptations at Birth

Cardiovascular Transition

• In utero: lungs are fluid-filled; gas exchange via placenta; pulmonary vascular resistance (PVR) is high; blood bypasses lungs via:
  • Foramen ovale (RA → LA)
  • Ductus arteriosus (PA → aorta)
  • Ductus venosus (umbilical vein → IVC)
• At birth:
  1. First breath → lungs expand → PVR falls dramatically
  2. Increased pulmonary blood flow → increased LA pressure → foramen ovale closes (functional closure)
  3. Rise in PaO2 → ductus arteriosus constricts → closes functionally in 12-24 hours; permanent closure in 2-3 weeks
  4. Umbilical arteries spasm → ductus venosus closes
• Preterm infants have higher risk of PDA persisting (lower oxygen sensitivity)

Respiratory Transition

• Fetal lung fluid is resorbed at birth (via squeezing in birth canal, lymphatics, circulatory absorption)
• Surfactant (Type II pneumocytes) essential for alveolar stability; production matures at ~34-36 weeks
• Surfactant deficiency → Respiratory Distress Syndrome (RDS) in preterm

Temperature Regulation

• Newborns are obligate heat losers (large surface area-to-volume ratio; poor insulation; limited brown fat mobilization in very preterm)
• Heat loss mechanisms: radiation (most important), conduction, convection, evaporation
• Term newborn can generate heat via non-shivering thermogenesis (brown adipose tissue/BAT metabolism)
• Target temperature: 36.5-37.5°C axillary; neutral thermal environment for preterm = incubator

Glucose Homeostasis

• Fetal glucose entirely from mother; at birth → glucose supply abruptly cut
• Newborns must rapidly activate gluconeogenesis and glycogenolysis
• Normal glucose threshold: >2.6 mmol/L (>47 mg/dL) after 4 hours of life
• Early feeding is the cornerstone of neonatal hypoglycemia prevention

---

8. Physiological Events in the First Week (Normal Variants)

---

9. Routine Newborn Care

Immediate After Birth

1. Dry and warm the infant immediately (prevents hypothermia)
2. Clear airway if needed (bulb syringe if secretions)
3. Assess Apgar score at 1 and 5 minutes
4. Delayed cord clamping: wait at least 30-60 seconds before clamping (improves iron stores, reduces IVH in preterm)
5. Skin-to-skin contact (kangaroo care): promotes bonding, thermoregulation, breastfeeding
6. Initiate breastfeeding within 1 hour of birth

Routine Prophylaxis (within first hours)

Newborn Screening (varies by country)

• Metabolic screen (heel-prick/Guthrie test): at 48-72 hours of age (after feeding established)
  • PKU (phenylketonuria), congenital hypothyroidism, galactosemia, CAH, maple syrup urine disease, homocystinuria, cystic fibrosis (IRT), sickle cell disease, biotinidase deficiency, fatty acid oxidation disorders, amino acid disorders
• Hearing screen (OAE or AABR): before discharge
• Pulse oximetry (CCHD screen): right hand and foot SpO2 after 24 hours
• Bilirubin (transcutaneous or serum): for jaundice assessment

Feeding

• Breastfeeding recommended exclusively for first 6 months (WHO)
• Colostrum (first 3-5 days): rich in IgA, leukocytes, proteins; immunological protection
• Normal feeding frequency: 8-12 feeds per day (on demand, approximately every 2-3 hours)
• Adequacy: 6+ wet diapers/day and regular stools after milk comes in (day 3-5)

---

10. Red Flags in the Newborn

---

Key Points Summary

• Normal term newborn: weight 2,500-4,000 g, length 48-52 cm, OFC 33-37 cm
• Apgar score at 1 and 5 min; 7-10 = normal; do NOT delay resuscitation for score
• Gestational age assessed by New Ballard score (neuromuscular + physical criteria)
• Physiological weight loss up to 10% expected; regain by 7-10 days
• Physiological jaundice starts day 2-5; jaundice <24 hours = always pathological
• Routine prophylaxis: Vitamin K (IM), erythromycin eye drops, Hepatitis B vaccine
• Primitive reflexes all present at birth; disappear with cortical maturation
• DDH: screen with Barlow (dislocates) and Ortolani (reduces); "clunk" = positive
• Key red flags: early jaundice, central cyanosis, absent femoral pulses, absent red reflex, failure to pass meconium/urine

---

• Textbook of Family Medicine, 9th Edition, Chapter 21 (The Normal Newborn)
• Rosen's Emergency Medicine - Concepts and Clinical Practice
• Tintinalli's Emergency Medicine: A Comprehensive Study Guide